Since, we had patients with varying treatment status, to exclude an effect of treatment on the results of TLR3/4 levels in EVs, we performed a sensitivity analyses by comparing levels of TLR3 in EVs between MS patients grouped based on treatment status (either on a disease modifying treatment or no DMT) and HCs. Here, TLR3 is linked to myeloid sarcoma.